82152 Planegg-Martinsried, de
+49 (89) 210228-40
4SC Announces Capital Increase
The Company intends to raise in the range of EUR 25 to 30 million. The proceeds will secure the further development of 4SC's current product pipeline. In particular, the focus will be on the further development of clinical and preclinical compounds against auto-immune and cancer indications, for which proof-of-concept is expected to be achieved within the next 24 months.
The subscription rights of the shareholders have been protected. The new shares with dividend rights from 1 January, 2009, can be obtained by shareholders in a ratio of 5:2 from 27 October until 10 November 2009. In the following any unsubscribed shares will be offered to new institutional investors. A public offer for the purchase of the new share capital will not occur. The approval of the new shares for trading at the Frankfurt Stock Exchange is not expected before November/December 2009. Further details of the capital increase will be published in the electronic Federal Register (Bundesanzeiger), which is expected on the 27 October, 2009.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.